Supplementary Table S1: LPV pediatric dosing guidelines

<table>
<thead>
<tr>
<th>body weight (kg)</th>
<th>WHO guidelines 2010</th>
<th>CHAPAS-2 Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Liquid (80/20 mg/mL)</td>
<td>Pediatric tablet (100/25mg)</td>
</tr>
<tr>
<td></td>
<td>mg</td>
<td>mg/m²</td>
</tr>
<tr>
<td>5-&lt;7</td>
<td>0.3</td>
<td>0.38</td>
</tr>
<tr>
<td>7-&lt;10</td>
<td>0.38</td>
<td>0.49</td>
</tr>
<tr>
<td>10-&lt;12</td>
<td>0.49</td>
<td>0.56</td>
</tr>
<tr>
<td>12-&lt;14</td>
<td>0.56</td>
<td>0.62</td>
</tr>
<tr>
<td>14-&lt;20</td>
<td>0.62</td>
<td>0.79</td>
</tr>
<tr>
<td>20-&lt;25</td>
<td>0.79</td>
<td>0.92</td>
</tr>
<tr>
<td>25-&lt;30</td>
<td>0.92</td>
<td>1.1</td>
</tr>
<tr>
<td>30-&lt;35</td>
<td>1.1</td>
<td>1.2</td>
</tr>
</tbody>
</table>

* Based on standard from pediatric oncology[11].
† Target daily LPV dosage of WHO 2010 is 230-350 mg/m² twice-daily (=460-700 mg/m² LPV daily dose)

Note: bold indicates where CHAPAS-2 protocol dosing differed from WHO 2010.

5 Note: bold indicates where CHAPAS-2 protocol dosing differed from WHO 2010. Footnote: No child in any cohort reported any problems knowing which bottle contained which drug on any formulation. No problems losing/breaking bottles were reported in either minitablet sprinkle/syrup cohort (3-<12m or 1-<4y) on any formulation. No problems with weight of the bottles, opening the bottles, the number or conspicuousness of the bottles or with losing/breaking capsules were reported on either formulation in the 1-4y minitablet sprinkle/syrup cohort or the 4->13y minitablet sprinkle/tablet cohort. No problems transporting bottles or vomiting medicine were reported on either formulation in the 4-<13y minitablet sprinkle/tablet cohort.
**Supplementary Figure S1**

**PK Cohort-A**
HIV-infected infants aged 3-<12 months (n=16)

**Protocol Arm 3**

**PK**
Lopinavir/r innovator syrup (n = 16)

**Wk 4**
Lopinavir/r novel minitabs (n = 16)

**Wk 8**

**PK Cohort-B**
HIV-infected children aged 1-<4 years (n=24)

**Protocol Arm 4**

**Randomise**

**PK**
Lopinavir/r novel minitabs (n = 12)

**PK**
Lopinavir/r innovator syrup (n = 12)

**PK**
Lopinavir/r novel minitabs (n = 12)

**PK**
Lopinavir/r innovator syrup (n = 12)

**Protocol Arm 5**

**PK**
Lopinavir/r generic tablets (n = 12)

**PK**
Lopinavir/r novel minitabs (n = 12)

**PK**

**PK Cohort-C**
HIV-infected children* aged 4-<13 years (n=24)

**Protocol Arm 1**

**Randomise**

**PK**
Lopinavir/r generic tablets (n = 12)

**PK**
Lopinavir/r novel minitabs (n = 12)

**PK**

**PK**
Lopinavir/r novel minitabs (n = 12)

**PK**
Lopinavir/r generic tablets (n = 12)